Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.
about
Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptorTargeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC)Tumor and stromal-based contributions to head and neck squamous cell carcinoma invasionCombining targeted agents and hypo- and hyper-fractionated radiotherapy in NSCLCProtein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancerOptimal management of the elderly patient with head and neck cancer: Issues regarding surgery, irradiation and chemotherapyGenome stability pathways in head and neck cancersA predictive phosphorylation signature of lung cancerEpidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacyThe intersection between DNA damage response and cell death pathwaysPhase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.Treatment of non-small cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: the NEAR protocol (NCT00115518).MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer.Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment.Combined treatment of adenoid cystic carcinoma with cetuximab and IMRT plus C12 heavy ion boost: ACCEPT [ACC, Erbitux® and particle therapy].Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx--TPF-Jeremiah Metzger Lecture. Targeted cancer therapyUnderstanding resistance to EGFR inhibitors-impact on future treatment strategiesInteraction of radiation therapy with molecular targeted agentsRandomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.Molecular Mechanisms that Regulate Epidermal Growth Factor Receptor InactivationPhase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303.RadioImmunotherapy for adenoid cystic carcinoma: a single-institution series of combined treatment with cetuximab.Simvastatin Enhances the Effects of Radiotherapy and Cetuximab on a Cell Line (FaDu) Derived from a Squamous Cell Carcinoma of Head and NeckEpidermal growth factor receptor inhibitors in colorectal cancer treatment: what's new?Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancerHigh ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area.Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab.Emerging drugs to treat squamous cell carcinomas of the head and neck.Evaluation of apoptogenic adenovirus type 5 oncolytic vectors in a Syrian hamster head and neck cancer modelNoncovalent functionalization of carbon nanovectors with an antibody enables targeted drug deliveryDynamic contrast-enhanced computed tomography to assess early activity of cetuximab in squamous cell carcinoma of the head and neck.Cetuximab-conjugated iron oxide nanoparticles for cancer imaging and therapy.Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment.Monoclonal antibodies and Fc fragments for treating solid tumors.Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivoA phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck.Noncovalent assembly of targeted carbon nanovectors enables synergistic drug and radiation cancer therapy in vivo.
P2860
Q24314620-94D0F53A-C5C3-49A9-8959-1E069A379A23Q26765429-86B1B2B8-5F60-4E1F-B188-E00CDFB0EB7FQ26825164-6AF02728-658E-4E23-874D-DAA4E1C11A4CQ26852202-7CDC1E17-0853-404D-8B70-5DD65A6193AFQ26852215-B4D3CEBD-39F8-400D-A446-4E2A4ECB15F0Q28083540-89F2F958-DC05-4773-B381-70FF37C435D7Q28391355-84FE242D-F8E6-4223-9423-F49E27223082Q28472058-F0CB5196-6EEA-4296-A572-36DBF4C56B7EQ28475894-BC2BD896-30C5-417B-9B52-1B03B5038E22Q28611423-92BACEB4-BED4-4602-925C-41F8F2BF0BB8Q30437778-79EA2146-C758-4809-955D-88302AB78D85Q33242719-453F5190-A888-4DCC-A69A-95CC01B89740Q33570512-6702D465-F581-4C13-94CD-F98D4803D004Q33644407-F3662CE4-4903-409A-9190-00D79B7D34B9Q33677975-3436F5CD-ED83-4F56-956A-2849EB81AA23Q33820302-81B466C8-AB04-4498-8358-2BDA86EAFA7AQ33906160-CE028681-BA9D-4C68-96B5-4E926CAA2F4DQ33958678-1F89FC70-1BD4-4C3B-BEDB-D645A098A013Q34088424-B13630AA-14CB-4030-AA34-9DDC886B8DE5Q34124285-0E65CB04-19EC-48DB-96ED-7A670E2BA1DEQ34171999-55A0966A-1C88-4EDF-ABE6-47AA93333919Q34213559-5DAC5B4E-93DA-47BB-A1DF-8BA27D5C9ED5Q34287666-CE654CFF-92BB-4DD8-A5BB-7E0143F101E9Q34331751-DBF29420-EAA2-4770-BBA9-B55AD1DB2141Q34369305-0B7975FA-0A40-4B99-82FD-BBC133DDBD21Q34382797-4E8B9819-CDDF-4092-9084-945A50386F15Q34455658-B44017A3-A7EC-4A3D-94AA-2EC680250760Q34622547-18D4026B-2F9F-4A6F-BC1C-C1F9AC67BF73Q34769944-F0C578C1-A4BC-444A-8DAF-EB407B4FFF8FQ35001415-588A3754-0962-4E05-B917-28973C3C7E63Q35098322-8612C359-2D7D-423C-8725-1D721CFA28A1Q35158716-F9A5DDBC-B1D8-4EFC-B1C4-F896D5EFD31AQ35177908-C1D5BBDC-9842-4CA8-A53B-3D1597D82CCFQ35184804-E5093DF3-5783-48B1-A1CA-F5C980F99F04Q35654360-DF1C4418-805A-4DF1-B23B-851699F01617Q35673572-E50335EA-D242-4EE4-94E0-3A90CA0DE687Q35699372-74E2D4EA-31A3-43A4-9E61-9E8E29F4E7A7Q35822882-88E342B8-D1E7-4B87-BCF0-D63CFFEAC3E1Q35836433-F8FC466D-F9C4-40C2-A6C6-2EE0AA050740Q35856908-373DF27B-D6D0-4D9B-A163-AC9C0E2EC263
P2860
Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Epidermal growth factor recept ...... rcinomas of the head and neck.
@ast
Epidermal growth factor recept ...... rcinomas of the head and neck.
@en
type
label
Epidermal growth factor recept ...... rcinomas of the head and neck.
@ast
Epidermal growth factor recept ...... rcinomas of the head and neck.
@en
prefLabel
Epidermal growth factor recept ...... rcinomas of the head and neck.
@ast
Epidermal growth factor recept ...... rcinomas of the head and neck.
@en
P2093
P1433
P1476
Epidermal growth factor recept ...... arcinomas of the head and neck
@en
P2093
P304
P407
P577
1999-04-01T00:00:00Z